Not all peptides are treated the same way by sports anti-doping authorities, and the differences are a useful window into both pharmacology and enforcement. Some are flatly banned at all times, some are only monitored, and most research-chemical peptides occupy a legal and testing gray zone that's worth understanding on its own terms.
The Relevant Category: WADA's S2 List
The World Anti-Doping Agency's Prohibited List includes a category, S2, covering peptide hormones, growth factors, related substances, and mimetics. Substances in this category are banned at all times, both in and out of competition, which is a stricter standard than categories that are only prohibited during competition. S2 exists because several peptide hormones can meaningfully affect muscle growth, recovery, red blood cell production, or metabolism in ways that are considered performance-enhancing.
Which Peptides Are Prohibited
Growth hormone-releasing peptides and growth hormone secretagogues, including GHRP-2, GHRP-6, ipamorelin, hexarelin, sermorelin, and CJC-1295, all covered individually elsewhere on this site, fall under S2 because they stimulate the body's own release of growth hormone. Growth hormone itself, IGF-1 and its analogs, and erythropoietin-stimulating agents are also prohibited under this category. These are banned regardless of whether an athlete has a legitimate off-label medical reason for using them, which is why athletes with a genuine medical need must apply for a Therapeutic Use Exemption rather than simply obtaining a prescription.
Why Some Peptides Are Hard to Detect
Detection difficulty varies a lot across this category. Many small peptides have short biological half-lives, meaning they clear the body quickly and leave a narrow detection window if testing relies on finding the substance itself in blood or urine. Growth hormone detection is a well-known example of this challenge: distinguishing a dose of recombinant growth hormone from the body's own natural growth hormone required years of method development, and testing labs now use a combination of an isoform differentiation test and a separate biomarker test that looks at downstream effects (like IGF-1 and a bone-collagen marker) rather than only searching for the hormone directly, precisely because direct detection alone wasn't reliable enough.
GLP-1 Drugs Are a Different Case
GLP-1 receptor agonists like semaglutide and tirzepatide, covered in this site's news coverage of WADA's 2027 list decision, are not currently on the Prohibited List. WADA added them to its separate monitoring program instead, a mechanism it uses to track patterns of use in sport without banning a substance outright, typically because there isn't yet a clear performance-enhancing rationale or sufficient evidence of misuse to justify prohibition. That could change in future list updates, but as of now, an athlete using a GLP-1 drug for an approved medical purpose is not violating anti-doping rules.
What This Means Practically
For a competitive athlete, the honest takeaway is that most of the recovery and growth-hormone-adjacent peptides marketed online, including several covered on this site as research-use-only compounds with thin human evidence, fall squarely under a prohibited category regardless of their legal status for purchase. Legal availability and anti-doping legality are two separate questions, and conflating them is a common and consequential mistake. Any athlete considering a peptide for a legitimate medical reason should talk to their team physician or national anti-doping organization about a Therapeutic Use Exemption before starting, rather than after a positive test.
The Bottom Line
Anti-doping testing for peptides is a moving target, shaped as much by what labs can reliably detect as by what's pharmacologically plausible. The practical rule for athletes is simple even where the science is complicated: a peptide being unregulated or easy to buy online says nothing about whether it's permitted in competition.